Literature DB >> 22189971

Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.

Karen F Underwood1, David R D'Souza, Maria Mochin-Peters, Adam D Pierce, Sravya Kommineni, Moran Choe, Jessica Bennett, Averell Gnatt, Bahru Habtemariam, Alexander D MacKerell, Antonino Passaniti.   

Abstract

The fat-soluble prohormone cholecalciferol (Vitamin D3) is a precursor of the circulating 25-OH Vitamin D3, which is converted by 1α-hydroxylase to the biologically active 1,25-OH Vitamin D3. Active Vitamin D3 interacts with the Vitamin D receptor (VDR), a transcription factor that plays an important role in calcium mobilization and bone formation. RUNX2 is a DNA-binding transcription factor that regulates target genes important in bone formation, angiogenesis, and cancer metastasis. Using computer-assisted drug design (CADD) and a microtiter plate-based DNA-binding enzyme-linked immunosorbent assay (D-ELISA) to measure nuclear RUNX2 DNA binding, we have found that Vitamin D3 prohormones can modulate RUNX2 DNA binding, which was dose-dependent and sensitive to trypsin, salt, and phosphatase treatment. Unlabeled oligonucleotide or truncated, dominant negative RUNX2 proteins were competitive inhibitors of RUNX2 DNA binding. The RUNX2 heterodimeric partner, Cbfβ, was detected in the binding complexes with specific antibodies. Evaluation of several RUNX2:DNA targeted small molecules predicted by CADD screening revealed a previously unknown biological activity of the inactive Vitamin D3 precursor, cholecalciferol. Cholecalciferol modulated RUNX2:DNA binding at nanomolar concentrations even in cells with low VDR. Cholecalciferol and 25-OH Vitamin D3 prohormones were selective inhibitors of RUNX2-positive endothelial, bone, and breast cancer cell proliferation, but not of cells lacking RUNX2 expression. These compounds may have application in modulating RUNX2 activity in an angiogenic setting, in metastatic cells, and to promote bone formation in disease-mediated osteoporosis. The combination CADD discovery and D-ELISA screening approaches allows the testing of other novel derivatives of Vitamin D and/or transcriptional inhibitors with the potential to regulate DNA binding and biological function.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22189971     DOI: 10.1002/jbmr.1504

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  10 in total

1.  A quantitative assay to study protein:DNA interactions, discover transcriptional regulators of gene expression, and identify novel anti-tumor agents.

Authors:  Karen F Underwood; Maria T Mochin; Jessica L Brusgard; Moran Choe; Avi Gnatt; Antonino Passaniti
Journal:  J Vis Exp       Date:  2013-08-31       Impact factor: 1.355

2.  The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells.

Authors:  Moran Choe; Jessica L Brusgard; Saranya Chumsri; Lekhana Bhandary; Xianfeng Frank Zhao; Song Lu; Olga G Goloubeva; Brian M Polster; Gary M Fiskum; Geoffrey D Girnun; Myoung Sook Kim; Antonino Passaniti
Journal:  J Cell Biochem       Date:  2015-10       Impact factor: 4.429

3.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

4.  Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Authors:  Hong Li; Ren-Jie Zhou; Guo-Qiang Zhang; Jian-Ping Xu
Journal:  Tumour Biol       Date:  2013-03-08

5.  Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells.

Authors:  Maria T Mochin; Karen F Underwood; Brandon Cooper; John C McLenithan; Adam D Pierce; Cesar Nalvarte; Jack Arbiser; Anna I Karlsson; Alexander R Moise; Jackob Moskovitz; Antonino Passaniti
Journal:  Microvasc Res       Date:  2014-10-02       Impact factor: 3.514

6.  Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells.

Authors:  Rama Garimella; Priyanka Tadikonda; Ossama Tawfik; Sumedha Gunewardena; Peter Rowe; Peter Van Veldhuizen
Journal:  Int J Mol Sci       Date:  2017-03-16       Impact factor: 5.923

7.  Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.

Authors:  Weiping Li; Shujuan Xu; Shuang Lin; Wei Zhao
Journal:  J Biomed Biotechnol       Date:  2012-10-04

8.  RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.

Authors:  Jessica L Brusgard; Moran Choe; Saranya Chumsri; Keli Renoud; Alexander D MacKerell; Marius Sudol; Antonino Passaniti
Journal:  Oncotarget       Date:  2015-09-29

9.  Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity.

Authors:  Myoung Sook Kim; Ramkishore Gernapudi; Eun Yong Choi; Rena G Lapidus; Antonino Passaniti
Journal:  Oncotarget       Date:  2017-08-10

Review 10.  RUNX family: Oncogenes or tumor suppressors (Review).

Authors:  Beatriz Andrea Otálora-Otálora; Berta Henríquez; Liliana López-Kleine; Adriana Rojas
Journal:  Oncol Rep       Date:  2019-05-06       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.